New cancer drug SGN-B6A tested in chinese patients – safety first
NCT ID NCT06549816
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This early-stage trial tested the safety of a drug called sigvotatug vedotin (SGN-B6A) in 6 Chinese patients with advanced solid tumors like lung, head and neck, and stomach cancers. The main goal was to see what side effects occur and how the body processes the drug. This is not a cure; it aims to control the disease while monitoring safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430023, China
Conditions
Explore the condition pages connected to this study.